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ABSTRACT
The non-invasive differentiation of malignant and benign biliary disease is a 
clinical challenge. Carbohydrate antigen 19-9 (CA19-9), leucine-rich α2-glycoprotein 
(LRG1), interleukin 6 (IL6), pyruvate kinase M2 (PKM2), cytokeratin 19 fragment 
(CYFRA21.1) and mucin 5AC (MUC5AC) have reported utility for differentiating 
cholangiocarcinoma (CCA) from benign biliary disease. Herein, serum levels of these 
markers were tested in 66 cases of CCA and 62 cases of primary sclerosing cholangitis 
(PSC) and compared with markers of liver function and inflammation. Markers panels 
were assessed for their ability to discriminate malignant and benign disease. Several 
of the markers were also assessed in pre-diagnosis biliary tract cancer (BTC) samples 
with performances evaluated at different times prior to diagnosis. We show that 
LRG1 and IL6 were unable to accurately distinguish CCA from PSC, whereas CA19-
9, PKM2, CYFRA21.1 and MUC5AC were significantly elevated in malignancy. Area 
under the receiver operating characteristic curves for these individual markers 
ranged from 0.73–0.84, with the best single marker (PKM2) providing 61% sensitivity 
at 90% specificity. A panel combining PKM2, CYFRA21.1 and MUC5AC gave 76% 
sensitivity at 90% specificity, which increased to 82% sensitivity by adding gamma-
glutamyltransferase (GGT). In the pre-diagnosis setting, LRG1, IL6 and PKM2 were 
poor predictors of BTC, whilst CA19-9 and C-reactive protein were elevated up to 2 
years before diagnosis. In conclusion, LRG1, IL6 and PKM2 were not useful for early 
detection of BTC, whilst a model combining PKM2, CYFRA21.1, MUC5AC and GGT 
was beneficial in differentiating malignant from benign biliary disease, warranting 
validation in a prospective trial. 
INTRODUCTION
Biliary tract cancer (BTC) comprises tumours of 
the gallbladder and bile ducts, the commonest form of 
which is cholangiocarcinoma (CCA). CCA cells tend 
to infiltrate and spread along the biliary tract such that 
patients often have minimal clinical symptoms and 
present late, usually with cholestasis and evidence of 
locally advanced or metastatic disease on imaging. 
Consequently, five-year survival rates in unresectable 
patients are under 10% [1]. CCA is predominantly 
diagnosed in the 7th decade of life and affects 1-2 per 
100,000 in the UK population [2], with a rising incidence 
worldwide [2–6]. 
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The aetiology of CCA has not been clearly defined 
and is usually considered to be sporadic, although certain 
recognised predisposing factors have been identified, 
including primary sclerosing cholangitis (PSC; CCA 
occurs in up to 40% of PSC patients), gallstones, hepatitis 
C, cirrhosis, prolonged or recurrent biliary infection, 
liver fluke infection and carcinogen exposure. A number 
of mutations have been found in known oncogenes and 
tumour suppressor genes in CCA tissue specimens, 
however, the frequency of these mutations has been 
difficult to accurately assess and this information remains 
clinically unusable. 
Indeterminate biliary strictures present a diagnostic 
challenge with multiple pathologies sharing similar clinical 
and radiological findings. In particular, the differentiation 
of CCA and PSC is difficult [7–9]. Endoscopic retrograde 
cholangiopancreatography (ERCP) following cross-
sectional radiology for lesion assessment and biopsy 
has a sensitivity for malignancy of only 9–57%, whilst 
endoscopic ultrasound used in conjunction with fine needle 
aspiration for visualization and sampling has a sensitivity 
of ~75% [10–13]. Novel cholangioscopic techniques have 
shown improved diagnostic accuracy compared to standard 
ERCP [14, 15]. Despite this, these invasive diagnostic 
procedures require highly-trained operators, are expensive 
to perform and can cause significant complications. Thus, 
non-invasive tests for differentiating CCA from benign 
pathologies are urgently needed.
Whilst efforts to discover effective blood-borne 
biomarkers for early detection are ongoing, the relative 
rarity of the disease and the frequent presence of 
cholestasis and cholangitis which can confound biomarker 
assays, have so far limited discovery efforts [16]. The 
best reported blood-borne tumour marker is carbohydrate 
antigen 19-9 (CA19-9), the sialylated Lewis (a) antigen, 
with the combination of CA19-9 and MRI/MRCP or 
ultrasound representing the most effective, cost-efficient 
and acceptable technique for screening and follow-up of 
CCA. However, ~7% of the population who are Lewis 
(a) antigen negative do not produce CA19-9 and it is also 
often elevated in benign conditions presenting with similar 
indications, including PSC, primary biliary cirrhosis, 
cholestasis and cholangitis [17]. Indeed, serum bilirubin 
levels are an independent predictor of serum CA19-9 
levels. The estimated sensitivity of CA19-9 in predicting 
CCA in the context of PSC is 38–89% with a specificity 
of 50–98% [18, 19]. Other reported serum markers include 
carcinoembryonic antigen (CEA) and carbohydrate antigen 
125/mucin 16 (CA125/MUC16), although they are elevated 
in only ~30% and 40–50% of cases, respectively [16]. 
One strategy to improve the diagnostic accuracy of 
CA19-9 may be to combine it with other biomarkers, as 
reported for bile galectin-3-binding protein (LGALS3BP) 
[20] and serum CEA [18]. Indeed, we have previously 
reported a combination of serum CA19-9, leucine-rich 
a2 glycoprotein 1 (LRG1) and interleukin 6 (IL6) that 
was capable of discriminating CCA from benign biliary 
strictures with an area under the receiver operating 
characteristics (ROC) curve (AUC) of 0.98, and 
independently of elevated bilirubin [21]. Other blood-
based markers with potential to improve diagnostic 
accuracy include mucin 5AC (MUC5AC) [22–25], soluble 
fragment of cytokeratin 19 (CYFRA21.1) [26–28] and the 
pyruvate kinase isoenzyme M2 (PKM2) [29–31].
In a search for improved non-invasive diagnostic 
markers of CCA, we have investigated serum levels of 
CA19-9, LRG1, IL6, MUC5AC, CYFRA21.1 and PKM2 
in a set of samples taken from patients diagnosed with 
CCA and PSC and tested combinations of these putative 
markers for differential diagnosis. Some of the candidates 
were also evaluated in pre-diagnosis samples from BTC 
and matched cancer-free controls to examine their value 
for early diagnosis.
RESULTS
Validation of a biomarker panel in patients with 
CCA compared with PSC
We previously reported a serum biomarker panel 
comprising of CA19-9, LRG1 and IL6 which was able 
to discriminate patients with CCA from benign biliary 
strictures with high accuracy [21]. Given that the sample 
size of the benign group used in this previous study was 
small (n = 13) and heterogeneous, testing of this biomarker 
panel in a larger, more homogeneous case control set was 
warranted. Thus, CA19-9, LRG1 and IL6 were measured 
in serum samples taken from 66 patients diagnosed with 
CCA and 62 diagnosed with PSC (Table 1). CA19-9 was 
confirmed as being significantly elevated in CCA cases 
(median 136.4 U/mL, interquartile range (IQR) 33.7–
427.1 U/mL) compared to the PSC group (median 15.86 
U/mL, IQR 7.9–41.5 U/mL; P < 0.0001). There was no 
significant difference in serum levels of LRG1 or IL6 
between the groups (Figure 1). Markers of liver function 
and inflammation were also assessed. ALP and TBIL were 
unchanged between the CCA and PSC groups, whilst GGT 
and CRP were elevated in CCA versus PSC (P = 0.011 
and P = 0.041, respectively) (Figure 1). ALP, TBIL, GGT 
and CRP levels were also positively correlated with one 
another (r > 0.34), and more so in the CCA group (r > 
0.41). When cases were stratified into high and low CRP 
groups, using the median value as a cut-off, both CA19-9 
and CRP maintained discriminatory ability, whilst GGT 
was only significant (P = 0.02) for the high CRP groups 
(data not shown).
Testing promising biomarkers for the differential 
diagnosis of CCA
Potential biomarkers PKM2, MUC5AC and 
CYFRA21.1 previously assessed by our group and others 
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[24, 27, 30, 32], were next tested in the study set. All three 
candidates were significantly elevated in malignant cases 
compared to benign controls (Figure 2A). PKM2 and 
MUC5AC maintained significance (P < 0.0001 and P < 
0.001, respectively) irrespective of CRP level, whereas 
CYFRA21.1 was only significant (P < 0.0001) when 
comparing the high CRP groups (data not shown). PKM2 
gave 75.8% sensitivity and 82.3% specificity at a cut-off of 
> 2.2 ng/mL, MUC5AC gave 60.6% sensitivity and 82.3% 
specificity at a cut-off of > 0.67 ng/mL and CYFRA21.1 
gave 65.2% sensitivity and 75.8% specificity at a cut-off of 
> 4.0 ng/mL (Table 3; Figure 2B). When intrahepatic cases 
(n = 12) were compared against extrahepatic CCA cases 
(n = 46), only PKM2 was significantly different between 
the groups (P = 0.022), being elevated in intrahepatic 
cases stage (Supplementary Figure 1). This suggests 
that any difference in treatment between the two groups, 
e.g. endoscopic evaluation and stenting, was not a major 
confounding factor, particularly involving an inflammatory 
response. Notably, none of the tested candidates showed 
significant differences in serum levels dependent upon 
TNM stage (Supplementary Figure 2).
Combined logistic regression models
Combinations of candidates were next tested, using 
logistic regression to generate models. The AUC for a 
model combining CA19-9, LRG1 and IL6 was only 0.63 
(Table 4), and so failed to validate our previous findings 
[21]. Combining PKM2 with CYFRA21.1, MUC5AC 
or CA19-9 gave AUCs of 0.85–0.88 with sensitivities 
ranging from 64-71% at 90% specificity, and PKM2 
was the marker that featured most commonly in the 
top models. Combining CYFRA21.1 and MUC5AC, 
did not significantly improve on using either candidate 
marker alone (Table 4). The best-performing 3-variable 
models ([PKM2, MUC5AC, CYFRA21.1] and [PKM2, 
CYFRA21.1, TBIL]) had AUCs of 0.90 (Figure 2B) and 
0.87 with sensitivities of 75.8% and 80.3%, respectively, 
at 90% specificity (Table 4). Addition of CA19-9 to the 
former model did not improve the AUC, and indeed, 
CA19-9 did not feature prominently in the best models. 
The best-performing model combined PKM2, MUC5AC, 
CYFRA21.1 and GGT with a sensitivity of 81.8%, 
specificity of 90% and an AUC of 0.90.
To address possible confounding effects of biliary 
obstruction on biomarker performance, samples were 
stratified into low and high TBIL groups based on 
the median as a cut-off (12.7 μmol/L) and diagnostic 
performance assessed for the two groups. For the low 
TBIL group (CCA n = 31; PSC n = 32), the performance 
of individual markers and combined models were 
generally better compared to the full study set, with the 
best model (PKM2; CYFRA21.1; MUC5AC) providing 
87.1% sensitivity at 90% specificity, with PKM2 again 
featuring prominently in the top models (Supplementary 
Table 1). Model performances for the high TBIL 
group (CCA n = 35; PSC n = 30) were generally lower 
compared to the full set, particularly those incorporating 
CYFRA21.1 (Supplementary Table 1). Thus the sensitivity 
of the PKM2; CYFRA21.1; MUC5AC model decreased 
to 65.7% at 90% specificity for the high TBIL group. 
The top models featured PKM2 and CRP or GGT and 
gave the same sensitivity of 74.3%. Conversely, models 
using CA19-9 or CRP showed modest improvement in 
performance in the high versus low TBIL groups.
Regression tree and random forest analysis 
Given that the discriminatory power of some of the 
markers changed when samples were stratified by TBIL or 
CRP, we wanted to test algorithms more suited to model 
any interactions between variables. A Classification and 
Regression Tree model gave 95% sensitivity at 71% 
specificity with an AUC of 0.83 using PKM2, CYFRA21.1 
and CA19-9 in the model  (Supplementary Figure 3). 
Logistic regression models were also compared with the 
random forest ensemble learning method for classification. 
Variable selection within the random forest algorithm 
reported proteins PKM2, CA19.9, CYFRA21.1, GGT 
and CRP as those having highest variable importance, 
whilst selection within the logistic regression reported 
PKM2, MUC5AC, CYFRA21.1, CRP, ALP and GGT. The 
performance of the two algorithms was similar: AUC = 
0.912 (sensitivity of 75.8% at specificity of 90%) for the 
random forest versus AUC = 0.909 (sensitivity of 81.8% at 
specificity of 90%) for the logistic regression. The results 
indicate that logistic regression remains a trustworthy 
classification algorithm for CCA versus PSC using the 
biomarkers reported herein.
Diagnostic performance of biomarkers in pre-
diagnosis samples
To assess the potential of the markers for early 
diagnosis of BTC, assays for TBIL, ALP, GGT, CRP, 
CA19-9, LRG1, IL6 and PKM2 were conducted on a set 
of 89 pre-diagnosis serum samples taken from 55 cases 
of BTC and 91 matched cancer-free controls identified 
from the UKCTOCS biobank (Table 2). The median 
time from sample collection to diagnosis was 31.5 
months. When all samples were considered, CA19-9 (P 
= 0.002), ALP (P = 0.006), GGT (P = 0.039) and CRP 
(P = 0.0007) were significantly elevated in BTC pre-
diagnosis samples compared to cancer-free controls, as 
was the proportion of samples with CA19-9 levels > 
37 U/mL (P = 0.038) (Supplementary Table 2). TBIL, 
LRG1, IL6 and PKM2 were not significantly elevated. 
CA19-9 provided 17% sensitivity at a specificity of 
93% using the standard cut-off value of > 37 U/mL with 
an optimised cut-off giving 53% sensitivity and 69% 
specificity (Table 5).
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In stratifying the samples by time to diagnosis, 
TBIL, LRG1, IL6 and PKM2 remained unchanged across 
the time groups. ALP was elevated only within 1 year 
of diagnosis, whilst CA19-9, CRP and GGT displayed 
increasing levels towards diagnosis, although the 
differences between cases and controls for GGT narrowly 
failed significance (Figure 3). CRP and CA19-9 were also 
significantly elevated 1-2 years before diagnosis, but not 
beyond. Combining LRG1, IL6 and PKM2 with CA19-9 
did not significantly improve the AUC compared to CA19-
9 alone, either for all samples or just those taken within 
1 year of diagnosis (Table 4). Combining CRP and ALP 
with CA19-9 also did not significantly improve the AUC 
compared to CA19-9 alone, either for all samples or just 
those within 1 year to diagnosis.
DISCUSSION
There are relatively few studies that have tested 
circulating biomarkers for CCA. This study aimed to 
validate previously proposed biomarkers and to investigate 
their use for early detection in the pre-diagnosis setting. 
Our previously reported biomarker panel of CA19-9, 
IL6 and LRG1 [21] did not perform as well in this larger, 
more homogeneous cohort of CCA and PSC patients. 
The inflammatory cytokine IL6 was previously found to 
be increased in the circulation of CCA patients [33–35] 
and was reported to synergistically induce the expression 
of LRG1 along with other inflammatory cytokines [36]. 
In the present cohort, IL6 and LRG1 were positively 
correlated (r = 0.339 in the CCA group), so it is perhaps 
unsurprising that we found no complementarity in using 
IL6 and LRG1 together. It is important to note that our 
previous study used a relatively small sample size, 
particularly of benign cases, which were heterogeneous 
in nature and displayed inconsistency in the levels of 
inflammatory markers between the groups. This is likely 
to have contributed to an exaggerated performance of IL6 
and LRG1 in our previous work.
PKM2, MUC5AC and CYFRA21.1 however, were 
all found to distinguish CCA from the PSC group. Pyruvate 
kinase is an enzyme regulating the final rate-limiting step 
of glycolysis, with the PKM2 isoform overexpressed 
in many cancer types and proposed to promote aerobic 
glycolysis (the Warburg effect). We previously showed 
that bile and plasma PKM2 were elevated in BTC and 
was a predictor of tumour progression [30]. The results 
presented herein corroborate PKM2 as a biomarker for 
Table 1: Demographics, clinical pathological data and biochemical profile of patient cohort
Variable Cholangiocarcinoma (CCA)
Primary sclerosing cholangitis 
(PSC) P value
Number of patients 66 62
Male:Female (%) 37:29 (46%) 42:20 (33%) 0.205
Age (years) 65 (31–86) 52 (19–85) < 0.0001
Stage (TNM)       I 3
                             II 13
                             IIIA 7
                             IIIB 15
                             IVA 13
                             IVB 6
                             Not specified 9
Tumour 
classification =      
Intrahepatic
Perihilar
Distal
Overlapping
Not specified
12
38
4
6
6
CA19-9 (U/mL) 136.4 (2.3–10000) 15.9 (1.7–10000) < 0.0001
CA19-9 > 37 U/mL (%) 49/66 (74%) 16/62 (26%) < 0.0001
Total Bilirubin (μmol/L) 15.3 (2.5–300.2) 11.4 (0.8–493.2) 0.316
CRP (mg/L) 8.14 (0.6–208.0) 5.48 (0.6–131.6) 0.041
ALP (U/L) 222 (51–880) 203 (40–1714) 0.801
GGT (U/L) 273 (36–2623) 213 (11–2689) 0.011
= Tumour classification followed the guidelines of [39]. Median values with (range) are given, unless indicated otherwise. 
P values were determined using the Student t, Mann Whitney or Fishers exact test.
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the differential diagnosis of CCA and PSC. When used 
in combination with MUC5AC and CYFRA21.1, PKM2 
added to diagnostic performance; at 90% specificity, 
the sensitivity increased from 60.6% for PKM2 alone to 
75.8% for the 3-marker panel and was further improved 
to 81.8% by addition of GGT. MUC5AC is a member 
of the membrane-bound and secreted epithelial mucin 
glycoprotein family and a previously reported serum 
marker of CCA [22, 25, 37]. In support of this, we showed 
that MUC5AC serum levels were increased in CCA 
versus PSC and contributed to the diagnostic performance 
of the biomarker panel. Serum levels of the cytokeratin 
19 fragment CYFRA21.1 also had diagnostic potential, 
again supporting previous reports [27, 28, 38]. Since both 
CYFRA21.1 and MUC5AC are involved in remodelling 
of the extracellular milieu, their elevation in CCA may 
suggest epithelial-mesenchymal transition and increased 
metastatic potential. However, neither CYFRA21.1, 
MUC5AC or any of the other candidates tested were 
significantly altered depending on TNM stage.
Notably, CA19-9 was not in any of the best 
biomarker panels and added little to diagnostic 
performance when used in combination. This may be 
indicative of an association with inflammation, and 
indeed the inflammatory marker CRP was also elevated 
in the CCA group. However, CA19-9, PKM2 and 
MUC5AC could similarly classify CCA from the benign 
group independently of CRP, whilst CYFRA21.1 was 
discriminatory only for the high CRP cases. Thus, the 
markers appear to be specific, performing well irrespective 
of underlying inflammatory status. Biliary obstruction is 
also known to affect tumour biomarker measurements 
in the context of CCA. We showed that whilst CA19-9, 
PKM2, CYFRA21.1 and MUC5AC could discriminate 
CCA cases independently of total bilirubin, the sensitivities 
of the biomarker panels at fixed specificity were reduced 
in high bilirubin cases, particularly those panels including 
CYFRA21.1. This suggests TBIL as a confounding factor 
for the differential diagnosis of CCA and should be taken 
into consideration for future validation studies. The exact 
causes of the interference are as yet unclear.
We next investigated a subset of the markers in 
the pre-diagnosis setting to assess their worth for early 
detection of BTC (CCA and gall bladder cancer). Rising 
serum levels of CA19-9, CRP and ALP were apparent 
in BTC cases towards diagnosis, and all 3 markers were 
significantly (P < 0.05) different between BTC and non-
cancer controls up to two years before diagnosis. For 
CRP and ALP, this suggests an inflammatory response is 
present and that liver/gall bladder function are affected 
Table 2: Clinical and sample characteristics of UKCTOCS BTC and control study set
Biliary tract 
cancer
Cancer-free 
controls P-value
Number of cases 55 91
Number of samples 89 91
Median age and range (years) 65 (52–75) 62 (50–77) 0.0004
Median time to spin and range (hours) 22.8 (0.5–46.0) 22.6 (1.5–46.0) 0.965
Median time from sample collection to diagnosis and range (months) 31.5 (0.9–66.6)
Tumour site: Intrahepatic
Extrahepatic
Gall bladder
Overlapping
29
4
12
10
Pre-diagnosis 
time group:
   0–1 y
   1–2 y
   2–3 y
    > 3 y
10
26
19
34
Table 3: Performance of single markers for discriminating CCA and PSC
Biomarker(s) Cut-off Sensitivity % (95% CI) Specificity % (95% CI) AUC (95% CI)
CA19-9 (U/mL) > 37.0 74.2 (62.0–84.2) 74.2 (61.5–84.5) 0.789 (0.71–0.87)
LRG1 (μg/mL) > 57.5* 4.5 (0.9–12.1) 91.9 (82.2–97.3) 0.562 (0.461–0.662)
IL6 (pg/mL) > 48.4* 80.3 (68.7–89.1) 17.7 (9.2–29.5) 0.543 (0.443–0.643)
PKM2 (ng/mL) > 2.2 75.8 (63.6–85.5) 82.3 (70.5–90.8) 0.839 (0.768–0.91)
CYFRA21.1 (ng/mL) > 4.0 65.2 (52.4–76.5) 75.8 (63.3–85.8) 0.732 (0.645–0.819)
MUC5AC (ng/mL) > 0.67 60.6 (47.8–72.4) 82.3 (70.5–90.8) 0.72 (0.631–0.809)
CI = confidence interval.*Cut-offs used in previous study [21].
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well in advance of diagnosis. However, these changes are 
not likely to be specific, and indeed for ALP, an elevation 
was not apparent in diagnosed CCA cases versus PSC. 
For CA19-9, sensitivity was 50% at 90% specificity (0–1 
year time group), and was not significantly improved by 
adding any other marker. Thus, it would be unsuitable for 
screening the general population, although may have some 
utility for screening high-risk groups. Disappointingly, 
LRG1, IL6 and PKM2 failed to show discriminatory 
potential. This is somewhat contrary to the elevation of 
LRG1 and IL6 in association with inflammation, since 
CRP was elevated in these prediagnosis cases. Whilst this 
suggests some specificity in the inflammatory response 
to BTC, we cannot rule out the possibility that CRP 
was elevated by chance in the BTC group due to other 
unreported conditions. The unaltered levels of PKM2 
prior to diagnosis may suggest that PKM2 elevation in 
the circulation occurs only after the tumour is established 
and in response to the increased metabolic demand of 
rapidly dividing cells. There are several weaknesses to our 
evaluation of markers of BTC in this pre-diagnosis set; the 
number of cases was relatively small, particularly in the 
0-1 year time group, details of tumour stage at diagnosis 
were not available, only post-menopausal women were 
sampled and appropriate benign controls were not 
available. 
In conclusion, a panel of previously identified 
circulating biomarkers (CA19-9, LRG1 and IL6) aimed 
Table  4: Performance of selected single and multivariate logistic regression models for discriminating 
CCA and PSC ranked in order of sensitivity at 90% specificity
Model Sensitivity (%) Specificity (%) AUC
PKM2, MUC5AC, CYFRA21.1, GGT 81.8 90.0 0.903
PKM2, CYFRA21.1, TBIL 80.3 90.0 0.868
PKM2, MUC5AC, CYFRA21.1, CRP 77.3 90.0 0.907
PKM2, MUC5AC, CYFRA21.1, ALP 77.3 90.0 0.899
PKM2, MUC5AC, CYFRA21.1, TBIL 75.8 90.0 0.899
LRG1, PKM2, MUC5AC, CYFRA21.1 75.8 90.0 0.899
PKM2, MUC5AC, CYFRA21.1 75.8 90.0 0.899
CA19.9, PKM2, MUC5AC, CYFRA21.1 75.8 90.0 0.897
PKM2, MUC5AC, CRP, ALP 74.2 90.0 0.895
CA19.9, PKM2, TBIL 74.2 90.0 0.867
CA19.9, PKM2, CYFRA21.1 72.7 90.0 0.87
PKM2, CYFRA21.1 71.2 90.0 0.869
CA19.9, PKM2, MUC5AC, CRP 69.7 90.0 0.891
LRG1, PKM2, MUC5AC, GGT 69.7 90.0 0.888
PKM2, CYFRA21.1, ALP 69.7 90.0 0.87
PKM2, CRP, GGT 69.7 90.0 0.866
PKM2, GGT 68.2 90.0 0.866
PKM2, CRP 68.2 90.0 0.85
PKM2, TBIL 68.2 90.0 0.848
PKM2, MUC5AC, CRP 66.7 90.0 0.889
CA19.9, PKM2 66.7 90.0 0.854
CA19.9, PKM2, MUC5AC 65.2 90.0 0.882
PKM2, MUC5AC 63.6 90.0 0.88
PKM2 60.6 90.0 0.842
CA19.9 50.0 90.0 0.801
CA19.9, CYFRA21.1 47.0 90.0 0.765
MUC5AC, CYFRA21.1 45.5 90.0 0.78
CYFRA21.1 40.9 90.0 0.73
CA19.9, LRG1, IL6 36.4 90.0 0.637
MUC5AC 30.3 90.0 0.728
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Table 5: Univariate and multivariate biomarker performance in 0-1 year time group and for all 
pre-diagnosis samples
Time group 
(years) Biomarker(s) Sensitivity (95% CI) Specificity (95% CI) AUC (95% CI)
0–1 (n = 10) CA19-9 80.0 (44.4–97.5) 69.2 (58.7–78.5) 0.770 (0.577–0.963)
TBIL 70.0 (34.8–93.3) 69.2 (58.7–78.5) 0.651 (0.458–0.845)
PKM2 60.0 (26.2–87.8) 50.0 (39.9–61.2) 0.525 (0.358–0.693)
CRP 70.0 (34.8–93.3) 73.6 (63.3–82.3) 0.728 (0.525–0.930)
GGT 90.0 (55.5–99.8) 65.9 (55.3–75.6) 0.793 (0.628–0.958)
ALP 80.0 (44.4–97.5) 63.7 (53.0–73.6) 0.771 (0.636–0.906)
CA19-9; PKM2 50.0 (20.0–80.0) 90.1 (74.7–100) 0.781 (0.580–0.983)
CA19-9; CRP 60.0 (30.0–90.0) 90.1 (58.2–100) 0.812 (0.615–1.00)
CA19-9; ALP 60.0 (30.0–90.0) 90.1 (40.7–100) 0.824 (0.661–0.988)
CA19-9; PKM2; LRG; IL6 60.0 (20.0–80.0) 90.1 (35.2–100) 0.803 (0.627–0.979)
All (n = 89) CA19-9 52.8 (41.9–63.5) 69.2 (58.7–78.5) 0.633 (0.552–0.715)
TBIL 42.7 (32.3–53.6) 67.0 (56.4–76.5) 0.505 (0.419–0.590)
PKM2 59.6 (48.6–69.8) 50.6 (39.9–61.2) 0.529 (0.444–0.614)
CRP 60.7 (49.8–70.9) 64.8 (54.1–74.6) 0.646 (0.565–0.727)
GGT 49.4 (38.7–60.3) 71.4 (61.0–80.4) 0.589 (0.505–0.673)
CA19-9; CRP 33.7 (14.6–48.3) 90.1 (78.0–95.6) 0.689 (0.611–0.767)
CA19-9; PKM2; LRG1; IL6 29.2 (11.2–40.5) 90.1 (75.8–95.6) 0.640 (0.559–0.722)
Figure 1: Box and whisker plots showing serum levels of CA19-9, LRG1 and IL6 in samples from PSC (n = 62; white 
boxes) and CCA patients (n = 66; grey boxes). ALP, GGT, TBIL and CRP were also measured in these samples. Whisker limits 
represent the 5th and 95th percentiles, the box limits represent the interquartile range, the horizontal line the median, and the ‘+’ the mean. 
P values (Mann-Whitney U test) are shown.
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Figure 2: (A) Box and whisker plots of serum levels of PKM2, CYFRA21.1 and MUC5AC in samples from PSC (n = 62; white boxes) 
and CCA patients (n = 66; grey boxes). Whisker limits represent the 5th and 95th percentiles, the box limits represent the interquartile range, 
the horizontal line the median, and the ‘+’ the mean. P values (Mann-Whitney U test) are shown. (B) ROC curves of PKM2, CYFRA21.1, 
CA19-9 and MUC5AC, alone and in combination (see Table 3 for performance characteristics).
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at the differential diagnosis of CCA failed to validate in 
this refined cohort of patients. Other promising markers 
(PKM2, CYFRA21.1 and MUC5AC) gave respectable 
classification performances in discriminating cancer cases 
from relevant benign controls and were independent of CRP 
and tumour site. The combination of PKM2, CYFRA21.1, 
MUC5AC and GGT effectively discriminated CCA from 
PSC with a sensitivity of 81.8% and specificity at 90%, 
and warrants validation in a prospective trial. A post hoc 
power calculation using PKM2 alone showed that 55 
samples per group would be sufficient to provide a power 
of 0.95 at an alpha of 0.05 and combination models using 
decision tree or random forest analysis performed similarly 
to logistic regression models. Thus, our models appears to 
be robust and would be reproducible in a larger cohort. In 
pre-diagnosis samples of BTC, CA19-9 was significantly 
elevated up to 2 years before diagnosis, but was not useful 
alone or in combination with other markers for accurate 
early detection. CYFRA21.1 and MUC5AC are yet to be 
tested in the pre-diagnosis setting. 
Figure 3: Box and whisker plots showing serum levels of ALP, GGT, CA19-9, CRP, PKM2, LRG1 and IL6 for cancer-
free controls (n = 91; white boxes) and BTC cases (n = 89; grey boxes) in UKCTOCS pre-diagnosis samples. Samples 
are grouped into different time-to-diagnosis groups. Whisker limits represent the 5th and 95th percentiles, the box limits represent the 
interquartile range, the horizontal line the median, and the ‘+’ the mean. Case and control groups were compared using the Mann-Whitney 
U test; P values are shown above the plots.
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MATERIALS AND METHODS
Patient samples
The study was conducted following ethical approval 
by the Joint UCL/UCLH Research Ethics Committee A 
(Ref.  06/Q0152/106) and Hannover Medical School 
Ethics Committee. Written informed consent was 
obtained from all patients. Blood samples were collected 
by venepuncture into Vacutainer SST tubes (BD, Franklin 
Lakes, NJ, USA) from patients with a confirmed diagnosis 
of CCA (n = 66) or PSC (n = 62) at University College 
London Hospital, the Royal Free Hospital London and the 
Hannover Medical School, between 01/2009 and 06/2015. 
Tumour site and classification followed the guidelines of 
[39]. Bloods were taken from CCA and PSC patients with 
either no prior endoscopic intervention, weeks to months 
after endoscopic treatment with ERCP (dilatation or stent 
insertion) or just before ERCP. All had a current stricture 
when included into the study. To 06/2015, none of the PSC 
patients were diagnosed with CCA. Blood was allowed 
to clot for 1 hr and separated by centrifugation at 2,200 
rpm for 10 min at 4°C. Serum was recovered, aliquoted 
and stored at –80°C until further use. Baseline patient 
demographics and clinical pathological data for this case 
control set are shown in Table 1.
Serum samples predating diagnosis of BTC and 
matched controls came from post-menopausal women 
recruited to the UK Collaborative Trial of Ovarian Cancer 
Screening (UKCTOCS) and were collected according 
to a standard operating procedure [40, 41]. This nested 
case-control study within UKCTOCS was approved by 
the Joint UCL/UCLH Research Ethics Committee A (Ref. 
05/Q0505/57). Informed consent was obtained from all 
volunteers and data was anonymised. Using volunteer 
NHS numbers, the Health and Social Care Information 
Centre cancer and death registers were interrogated for 
UKCTOCS participants who were subsequently diagnosed 
with CCA or gall bladder cancer (ICD10 codes C22.1/9, 
C23, C24.0/8). There were 55 cases of BTC identified 
(prior to Feb 2009) with 89 samples taken from these 
cases which were categorised into pre-diagnosis time 
groups (Table 2). Cases were matched with cancer-free 
controls (n = 91) by age (± 5 years), regional collection 
centre (same) and collection date (same).
Serum assays
Standard blood tests including liver biochemistry 
(total bilirubin (TBIL), alkaline phosphatase (ALP), 
gamma-glutamyl transferase (GGT)), C-reactive protein 
(CRP) and CA19-9 (Cobas CA19-9 CLIA; Roche and 
Fujirebio Diagnostics) were carried out at the Clinical 
Biochemistry service of UCLH. Samples were evaluated 
for the other candidate biomarkers using the following 
commercial ELISA kits at the dilutions specified and 
with the indicated intra-assay CVs: human LRG1 ELISA 
kit (IBL International, Hamburg, Germany; 1:2000; CV 
= 5.5%), human IL-6 ELISA Kit (Pierce Biotechnology, 
Rockford, IL, USA; 1:5; CV = 6.7%), human PKM2 
ELISA kit (Cloud-Clone Corp. Wuhan, China; 1:10; 
CV = 10.3%), human cytokeratin fragment antigen 21-1 
(CYFRA21.1) ELISA Kit (Cusabio, Wuhan, China; 
1:5; CV = 8.1%) and human MUC5AC ELISA Kit 
(Elabscience, Bethesda, MD, USA; 1:2; CV = 17.4%). 
Statistical analysis and biomarker modelling
Statistical analyses were carried out using GraphPad 
Prism V5 and R 3.4.1 software packages. Continuous data 
between clinical groups were compared using the Mann-
Whitney U-test for non-parametric data and the Student 
t-test for normally distributed data. The recommended 
clinical cut-off of 37 U/mL was used for CA19-9 and 
defined cut-offs for LRG1 (57.5 μg/mL) and IL6 (48.4 
pg/mL) were the optimal points for sensitivity and 
specificity from a previous study [21]. Multivariable 
logistic regression analysis was used to examine the inter-
relationship between serum biomarkers, liver function 
tests, biliary obstruction and cancer likelihood. The 
number of variables in models was restricted to ensure 
performance of models was reproducible without risk 
of overfitting; making sure that the one in ten rule was 
satisfied [42, 43]. ROC curves were generated and AUCs 
obtained and compared for single and combined biomarker 
models for discriminating CCA from PSC or between BTC 
cases and cancer-free controls in different time to diagnosis 
time groups for the UKCTOCS cohort. DeLong’s test was 
used to assess differences between ROC curves. P values 
< 0.05 were considered significant. Sensitivities at fixed 
specificity (90%) were calculated for all biomarkers and 
combinations. Classification and Regression Tree analysis 
was performed using the RPART package in R. Logistic 
regression models were also compared with the random 
forest ensemble learning method for classification [44] 
using R packages: ‘randomForest’ for implementation 
of the random forest algorithm, ‘VSURF’ for variable 
selection within the random forest and ‘MASS’ for the 
variable selection using the Akaike Information Criterion 
for the logistic regression models.
Abbreviations
CA19-9, carbohydrate antigen 19-9; LRG1, leucine-
rich a2-glycoprotein; IL6, interleukin 6; PKM2, pyruvate 
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MUC5AC, mucin 5AC; BTC, biliary tract cancer; 
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